

Transforming Tumor Research: Engineering MHCs as Versatile Reagents

Shicheng Chen¹, Xiangzhong Zheng¹, Juan Liu¹, Jia Cui¹, Jiamin Wang¹, Yuting Shi¹, Huaiyu He¹, Mallory Griffin¹, Xiaoyuan Ran¹, Man-Hee Suh¹




Download a digital copy of the poster

Introduction

The Major Histocompatibility Complex (MHC) is a group of cell surface molecules essential for adaptive immunity. MHC participates in antigen presentation to T cells and trigger downstream immune responses. The absence of dependable, multifaceted MHC reagents has been a hindrance in the therapeutic development against cancers. To address this unmet need, we developed MHC molecules in multiple formats with high versatility. These improved, highly active MHC molecules have the potential to facilitate T cell or TCR-based therapeutic research and development.


Form 1: Bacteria-Refolded MHC for Broad, High-Throughput Studies



Bacteria-refolded MHC molecules are produced by expressing the heavy chain and β 2-microglobulin separately in *E. coli*, followed by an in vitro refolding process in the presence of synthetic peptides. The high flexibility and scalability enables large-scale, high-throughput production of customized pMHC complexes of multiple peptides, suitable for applications such as tetramer staining, T cell profiling, as well as structural studies.

Form 2: Mammalian-Expressed Single-Chain Trimer MHC with High Stability and Physiological Presentation

The single chain trimer (SCT) MHC molecule is an engineered construct in which the MHC heavy chain (HLA), β 2-microglobulin, and a specific peptide are genetically linked into a single polypeptide chain. This design ensures stable, homogenous presentation of the peptide-MHC with normal post-translational modifications in mammalian cells that can overcome the caveats often seen in the *E. coli* refolded MHC-peptide complex. The SCTs are particularly advantageous for screening studies targeting specific peptides.



Both refolded and SCT monomers exhibit high purity and robust bioactivity in cell and non-cell based assays.

We evaluated the protein purity and the bioactivity of bacteria-refolded and mammalian-expressed SCT. As expected, both formats show high purity in HPLC and robust binding to their target TCRs in various assays, demonstrating their capability in diverse research applications.





Figure 1. Bacteria-refolded MHC. (A) The purity of HLA-A*11:01 KRAS G12V Monomer is greater than 95%. (B) Immobilized HLA-A*11:01 KRAS G12V Monomer at 0.5 μ g/ml (100 μ l/well) on the plate. Dose response curve for Anti-B2M Antibody with the EC₅₀ of 8.5 ng/ml. (C) KRAS G12V-specific TCR-HEK293T cells were stained with PE-Labeled HLA-A*11:01 KRAS G12V Tetramer. Non-transfected HEK293T cells and PE-Labeled proteins were used as a negative control. **Mammalian SCT MHC.** (D) The purity of Biotinylated HLA-A*02:01 PRAME Monomer is greater than 95%. (E) Immobilized Biotinylated HLA-A*02:01 PRAME Monomer at 1 μ g/ml (100 μ l/well) on the streptavidin precoated plate. Dose response curve for HLA-A*02:01 PRAME-specific TCR with the EC₅₀ of 4.8 ng/ml. (F) PRAME-specific TCR-HEK293T cells were stained with Biotinylated HLA-A*02:01 PRAME monomer, followed by SA-PE conjugation. Non-transfected HEK293T cells and PE-Labeled proteins were used as negative controls.

Human-Murine Chimeric MHC is potential for higher antibody screening efficiency.

Many TCR-mimic antibodies obtained in immunization are targeting MHC I α 3 and β 2m domains, which will not bind to the critical peptide binding pocket. Here, we designed the chimeric human-murine SCT MHC by replacing the human α 3 and β 2m domains with murine ones and performed further engineering to maintain the structural and functional integrity. This should increase the likelihood of generating peptide-specific antibodies, making screening less labor-intensive.




We examined the performance of our fluorescent prMHC tetramers by loading PRAME peptides (SLLQHLIGL) onto PE-labeled peptide-ready HLA-A* 02:01 tetramers and tested their binding specificity with HEK293 cells with or without PRAME TCR expression. As expected, the loaded HLA-A* 02:01 tetramers exhibited robust and specific binding only to cells expressing PRAME TCR.

Figure 4. FACS analysis of HEK293 cells with or without expressing PRAME specific TCR using PE-labeled pr HLA-A*02:01 tetramers loaded with irrelevant or PRAME(SLLQHLIGL) peptides.

Form 3: Peptide-Ready MHC (prMHC) for Rapid Antigen Loading & Screening

We have developed a peptide-ready MHC in which MHC molecules are stabilized without the presence of peptides. These time-saving, ready-to-load MHCs allow convenient, rapid loading of in-house prepared peptide libraries just at room temperature with no UV-induced peptide exchange required. Our prMHC simplifies the process and enhances the scope of research, making it a versatile and invaluable tool in the field of immunology and beyond.



Peptide-loaded prMHC monomers perform equally to SCT pMHC monomers

We demonstrated, by ELISA and SPR, that the prMHC monomer, once loaded with the specific antigenic peptides, are able to bind to antigen-specific TCRs with equivalent performance to SCT monomers.





Figure 3. Head-to-head comparison between prMHC and SCT MHC monomers. SPR analysis between JDI41b1 TCR with (A) empty prHLA-A*11:01 monomer, no binding, (B) prHLA-A*11:01 monomer loaded with KRAS G12D peptide, Affinity Constant 14.9 μ M, and (C) HLA-A*11:01 KRAS G12D SCT monomer, Affinity Constant 9.0 μ M. (D) Immobilized JDI41b1 TCR at 2 μ g/mL (100 μ l/well) on the plate. Dose-response curves of the above three MHC monomers with EC₅₀ of 20.57/0.11/0.17 μ g/mL, respectively.

Peptide-loaded prMHC tetramers shows robust signals in cell sorting



We examined the performance of our fluorescent prMHC tetramers by loading NY-ESO-1 peptides onto FITC-labeled peptide-ready HLA-A* 02:01 tetramers and tested their binding specificity with Jurkat cells with or without NY-ESO-1-specific 1G4 TCR expression. As expected, the loaded HLA-A* 02:01 tetramers exhibited robust and specific binding only to cells expressing 1G4 TCR.

Figure 4. FACS analysis of Jurkat cells with or without expressing NY-ESO-1 specific 1G4 TCR using FITC-labeled pr HLA-A*02:01 tetramers loaded with irrelevant or NY-ESO-1 peptides.

Conclusion

KACTUS high-quality refolding and SCT MHCs have equal performances on bioactivity assays, making it a powerful tool for TCR-based therapeutic research applications.

KACTUS proprietary prMHCs cover common HLA alleles such as HLA-A 11:01, HLA-A 02:01, HLA-A 02:03, HLA-A 03:01, etc., which can be utilized for highly efficient neoantigen loading, with robust binding performance in SPR, ELISA and FACS assays, equivalent to SCT MHCs.